Gainers
-
Eyenovia Inc (NASDAQ: EYEN) shares
rose 64.3 percent to $4.32 in pre-market trading after the company disclosed that its MIST-1 study met primary endpoint.
-
Co-Diagnostics Inc (NASDAQ: CODX) rose
33.6 percent to $1.49 in pre-market trading after the company reported the sale of $3 million of preferred shares, convertible
to common stock at a fixed price of $1.20 per share.
-
Mellanox Technologies, Ltd. (NASDAQ: MLNX) rose 13.8 percent to $92.94 in pre-market trading after Reuters reported
that Intel offered up to $6 billion for the company.
-
Turtle Beach Corporation (NASDAQ: HEAR) rose 10.7 percent to $15.70 in pre-market trading after falling 3.01
percent on Tuesday.
-
Advanced Micro Devices, Inc. (NASDAQ: AMD) shares rose 10.6 percent to $21.29 in pre-market trading despite reporting
a fourth-quarter sales miss. Fourth-quarter earnings came in at 8 cents per share, falling in-line with analyst estimates.
Revenues came in at $1.42 billion, missing estimates by $30 million. The company issued first-quarter sales guidance of $1.2
billion.
-
Grindrod Shipping Holdings Ltd. (NASDAQ: GRIN) rose 7.2 percent to $6.75 in pre-market trading after dropping 7.35
percent on Tuesday.
-
Boeing Co (NYSE: BA) rose 6.7 percent to
$389.50 in pre-market trading after the company posted upbeat Q4 results and issued strong FY19 forecast.
-
Vale S.A. (NYSE: VALE) shares rose 6.6
percent to $12.25 in pre-market trading after gaining 2.50 percent on Tuesday.
-
Hailiang Education Group Inc. (NASDAQ: HLG) rose 5.7 percent to $36.67 in pre-market trading after declining 6.22
percent on Tuesday.
-
ICICI Bank Limited (NYSE: IBN) rose 5.3
percent to $10.21 in pre-market trading after reporting Q3 earnings.
-
Apple Inc. (NASDAQ: AAPL) rose 5.2
percent to $162.61 in pre-market trading after the company reported stronger-than-expected results for its first quarter. The
company issued weak second-quarter sales guidance.
-
Nevro Corp. (NASDAQ: NVRO) shares rose
5.2 percent to $50.00 in pre-market trading after gaining 2.54 percent on Tuesday.
-
Box, Inc. (NYSE: BOX) rose 4.8 percent to
$20.70 in pre-market trading after declining 2.76 percent on Tuesday.
-
Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) rose 3.8 percent to $6.10 in pre-market trading.
-
C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) rose 3.6 percent to $89.75 in pre-market trading following upbeat Q4
earnings.
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.
Check out these big penny stock gainers and
losers
Losers
-
AC Immune SA (NASDAQ: ACIU) shares
fell 39.4 percent to $6.50 in pre-market after the company disclosed that its collaboration partner Roche is discontinuing
Phase III CREAD 1 and 2 studies of crenezumab in Alzheimer's disease.
-
Trevena Inc (NASDAQ: TRVN) fell 15.8
percent to $1.07 in pre-market trading after reporting a $10 million registered direct offering of common stock.
-
Juniper Networks, Inc. (NYSE: JNPR) fell
11.6 percent to $24.70 in pre-market trading. Juniper reported upbeat earnings for its fourth quarter, while sales missed
views. The company also issued weak Q1 guidance.
-
8x8, Inc. (NASDAQ: EGHT) fell 10.5
percent to $17.28 in pre-market trading after reporting a third-quarter sales miss. Earnings came in at $(0.06) per share.
-
Align Technology, Inc. (NASDAQ: ALGN)
fell 8.5 percent to $203.06 in pre-market trading after the company issued weak Q1 earnings forecast.
-
Golden Ocean Group Limited (NASDAQ: GOGL) fell 8.5 percent to $4.98 in pre-market trading.
-
PG&E Corporation (NYSE: PCG) fell 3.4
percent to $13.51 in pre-market trading after rising 16.49 percent on Tuesday.
-
AT&T Inc. (NYSE: T) fell 3.1 percent to
$29.75 in pre-market trading. AT&T reported in-line earnings for its fourth quarter, while sales missed estimates.
-
Biogen Inc. (NASDAQ: BIIB) fell 3.1
percent to $324.12 in pre-market trading after the company posted Q4 results.
-
Novartis AG (NYSE: NVS) shares fell 2.2
percent to $84.71 in pre-market trading following downbeat Q4 earnings.
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.